The HPS3 Knockout HT29 Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population designed for targeted disruption of the HPS3 gene in the human colorectal adenocarcinoma HT29 cell line. This product provides a loss-of-function model in which HPS3 expression is abrogated across a heterogeneous cell pool, enabling robust investigation of HPS3-dependent processes without the constraints of clonal selection. The polyclonal format preserves biological variability inherent to pooled knockout populations, making it suitable for studying pathway modulation under physiologically relevant conditions while minimizing potential clone-specific artifacts.
The HT29 cell line is an established human colorectal adenocarcinoma model characterized by epithelial morphology and widely employed in cancer biology research. It harbors mutations in key oncogenic pathways, including APC and ??-catenin, rendering it a valuable system for examining Wnt signaling, tumor metabolism, and metastatic behavior. In colorectal cancer studies, HT29 cells exhibit modulated lysosomal activity and autophagy, both of which intersect with HPS3-mediated organelle biogenesis. This host background thus offers a clinically pertinent platform for dissecting the interplay between lysosome-related organelle function and colorectal cancer pathogenesis.
HPS3 encodes a subunit of the biogenesis of lysosome-related organelles complex-2 (BLOC-2), which is essential for the biogenesis and protein trafficking to lysosome-related organelles. Within this complex, HPS3 interacts with HPS5 and HPS6, and functionally cooperates with the AP-3 complex, as well as the small GTPases Rab32 and Rab38, to regulate vesicular transport. Upstream, HPS3 expression is transcriptionally regulated by TFEB and MITF, master regulators of lysosomal biogenesis and autophagy. Downstream, HPS3 loss impairs critical effectors such as LC3B, SQSTM1/p62, LAMP1, and Cathepsin D, leading to defects in autophagic flux, lysosomal acidification, and endosomal trafficking. Disruption of the BLOC-2 complex thereby cascades into broader functional deficits across the autophagy-lysosome pathway and melanosome maturation.
In the HT29 colorectal adenocarcinoma context, HPS3 knockout disrupts BLOC-2-dependent lysosome-related organelle biogenesis, yielding atypical lysosomal morphology and impaired autophagic clearance. This dysfunction is expected to perturb cellular metabolism, alter Wnt signaling dynamics, and compromise tumor cell migration, as lysosomal activity modulates nutrient sensing and cell adhesion. The model thus enables dissection of how lysosomal integrity influences colorectal cancer aggressivity. Additionally, Hermansky-Pudlak syndrome type 3-related phenotypes, such as pigmentation defects and lysosomal storage-like features, can be partially recapitulated, linking hereditary lysosomal disorders to cancer cell biology.
These HPS3 knockout polyclonal cells are suited for diverse research applications, including autophagy research, lysosomal biology, Hermansky-Pudlak syndrome modeling, and drug trafficking studies. They provide a powerful tool to dissect how HPS3 integrates with the autophagy-lysosome pathway in cancer. Representative assays compatible with this model include Western blotting and RT-qPCR for HPS3 confirmation, LysoTracker staining and lysosomal pH measurement to assess organelle integrity, Cathepsin activity assays, and autophagic flux analysis via LC3 turnover. Immunofluorescence for LAMP1 can visualize lysosomal distribution, while cell viability, wound healing, and drug sensitivity assays probe functional outcomes. For more information, please contact Ascent Research.
